ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,721 to 4,740 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
EHR-based Alert vs Usual Care: Percentage of Patients on ARBs111 of 685

85 of 625

2.6 points

-1.3 to 6.4

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

EHR-based Alert vs Usual Care: Percentage of Patients on Beta Blockers606 of 685

521 of 625

5.1 points

1.3 to 8.9

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

EHR-based Alert vs Usual Care: Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy176 of 685

117 of 625

7.0 points

2.5 to 11.4

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

EHR-based Alert vs Usual Care: Percentage of Patients on MRAs232 of 685

203 of 625

1.4 points

-3.7 to 6.5

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

EHR-based Alert vs Usual Care: Percentage of Patients on ARNIs334 of 685

285 of 625

3.2 points

-2.2 to 8.5

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

EHR-based Alert vs Usual Care: Percentage of Patients on ACE Inhibitors83 of 685

92 of 625

-2.6 points

-6.3 to 1.1

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

EHR-based Alert vs Usual Care: Rate of One-year All-cause Mortality75 of 685

68 of 625

0.1 points

-3.4 to 3.4

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

EHR-based Alert vs Usual Care: Percentage of Patients on SGLT2 Inhibitors144 of 685

103 of 625

4.5 points

0.3 to 8.7

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

EHR-based Alert vs Usual Care: deaths from any cause75 of 685

68 of 625

0.1 points

-3.4 to 3.4

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

EHR-based Alert vs Usual Care: Rate of 30-day All-cause Emergency Department Visits86 of 685

77 of 625

0.2 points

-3.4 to 3.8

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

EHR-based Alert vs Usual Care: Rate of 30-day Hospital Admission47 of 685

63 of 625

-3.2 points

-6.3 to -0.2

1,310NCT04514458

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

CHG Cloth vs Placebo Cloth: Number of Participants With Incisional SSI17 of 662

24 of 647

-1.1 points

-3.1 to 0.8

1,309NCT02402907

STRIPES Study: Study To Reduce Infection Post cEsarean Section

CHG Cloth vs Placebo Cloth: Number of Participants With Endometritis0 of 662

1 of 647

-0.2 points

-0.9 to 0.4

1,309NCT02402907

STRIPES Study: Study To Reduce Infection Post cEsarean Section

Regional Anesthesia vs General Anesthesia: Satisfaction With Care85 of 647

97 of 661

-1.5 points

-5.3 to 2.2

1,308NCT02507505

Regional Versus General Anesthesia for Promoting Independence After Hip Fracture

RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose) vs Placebo Matching RotaTeq™: serious adverse events21 of 649

28 of 658

-1.0 points

-3.2 to 1.1

1,307NCT00092443

Dose Confirmation Efficacy Study (V260-007)

Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel: deaths from any cause107 of 652

77 of 655

4.7 points

0.9 to 8.4

1,307NCT00805194

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel: serious adverse events224 of 652

206 of 655

2.9 points

-2.2 to 8.0

1,307NCT00805194

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Treatment Period 2: Group 1 vs Treatment Period 2: Group 2: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24552 of 644

496 of 662

10.8 points

6.5 to 15.0

1,306NCT02409667

Plaque Psoriasis Efficacy and Safety With Secukinumab

SB204 4% vs Vehicle Gel: deaths from any cause0 of 654

1 of 652

-0.2 points

-0.9 to 0.4

1,306NCT02672332

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

SB204 4% vs Vehicle Gel: serious adverse events0 of 654

4 of 652

-0.6 points

-1.6 to 0.1

1,306NCT02672332

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=237"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=237

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04514458-0f250ec9",
        "title": "EHR-based Alert vs Usual Care: Percentage of Patients on ARBs",
        "summary": "111 of 685 against 85 of 625; risk difference 2.6 points, 95% interval -1.3 to 6.4; NCT04514458, Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure",
        "record": "/library/comparisons/NCT04514458-0f250ec9",
        "nct_id": "NCT04514458",
        "kind": "outcome",
        "participants": 1310,
        "risk_difference": {
          "value": 0.02604379562043796,
          "lower": -0.012784357833962319,
          "upper": 0.06446831747631585
        },
        "group_1": "111 of 685",
        "group_2": "85 of 625",
        "difference": "2.6 points",
        "interval": "-1.3 to 6.4",
        "trial_title": "Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure"
      },
      {
        "id": "NCT04514458-166652b4",
        "title": "EHR-based Alert vs Usual Care: Percentage of Patients on Beta Blockers",
        "summary": "606 of 685 against 521 of 625; risk difference 5.1 points, 95% interval 1.3 to 8.9; NCT04514458, Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure",
        "record": "/library/comparisons/NCT04514458-166652b4",
        "nct_id": "NCT04514458",
        "kind": "outcome",
        "participants": 1310,
        "risk_difference": {
          "value": 0.051071532846715284,
          "lower": 0.013419667922568282,
          "upper": 0.089150727517845
        },
        "group_1": "606 of 685",
        "group_2": "521 of 625",
        "difference": "5.1 points",
        "interval": "1.3 to 8.9",
        "trial_title": "Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=238",
  "request_id": "a0OjrcUZuli-coPm"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?